Therapeutic effect of (+)-cyanidanol-3 in toxic alcoholic liver disease and in chronic active hepatitis.
(+)-Cyanidanol-3 is considered to have cytoprotective effect in toxic liver injury. A randomized clinical trial was carried out in alcoholic precirrhotic patients and in chronic active hepatitis with (+)-cyanidanol-3 versus placebo. The daily dose of the drug was 1.5-2.0 g for a one-year period. A: Toxic alcoholic precirrhotic liver disease: 38 patients were treated with (+)-cyanidanol-3, 36 with placebo. We found significant improvement in the subjective symptome like asthenia and anorexia, and in serum aspartate-transaminase (GOT) levels. However, it is possible that the improvement was in part due to abstinence from alcohol. B: Chronic active hepatitis: previously introduced continuous prednisolone therapy (10-15 mg/day) was combined with (+)-cyanidanol-3 in 13 patients and with placebo in 12 controls. The results showed a more favourable, but not significantly better response in patients receiving (+)-cyanidanol-3 versus placebo. We concluded that the drug might be of benefit in some cases with chronic active hepatitis as an adjunct to corticoid therapy.
D000328:Adult; D000368:Aged; D001578:Benzopyrans / Q000627:therapeutic use*; D002392:Catechin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006519:Hepatitis, Alcoholic / Q000188:drug therapy*; D006521:Hepatitis, Chronic / Q000188:drug therapy*; D006801:Humans; D008099:Liver / Q000187:drug effects*; D008111:Liver Function Tests; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use
D001578:Benzopyrans; D002392:Catechin; D011239:Prednisolone